Sunitinib (SUTENT®) for the treatment of metastatic renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 8, Issue 11, 2008, Pages 1723-1731

  Hutson, Thomas E ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Metastatic; Platelet derived growth factor; Renal cell carinoma; Sunitinib; Vascular endothelial growth factor

Indexed keywords

2 METHOXYESTRADIOL; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; GEFITINIB; INTERLEUKIN 2; INTERLEUKIN 21; LEVOTHYROXINE; PERIFOSINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SU 12662; SUNITINIB; TEMSIROLIMUS; TICILIMUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER INHIBITION; CAPILLARY LEAK SYNDROME; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FATIGUE; HAND FOOT SYNDROME; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LONGITUDINAL STUDY; LUNG TOXICITY; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NONHUMAN; OLIGURIA; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; THYROID DISEASE; THYROID FUNCTION TEST; ANIMAL; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRROLES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 60849102835     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.11.1723     Document Type: Review

References (64)

1. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J. Urol. 176(6 Pt 1), 2353-2358 (2006).
2. Hutson TE. Renal cell carcinoma: diagnosis and treatment, 1994-2003. Proc. Bayl. Univ. Med. Cent. 18(4), 337-340 (2005).
3. Ljungberg B, Hanbury DC, Kuczyk MA et al. Renal cell carcinoma guideline. Eur. Urol. 511(6), 1502-1510 (2007).
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer (2008).
5. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar A Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20 (1), 289-296 (2002).
6. van Spronsen DJ, Mulders PF, De Mulder PH. Novel treatments for metastatic renal cell carcinoma. Crit. Rev. Oncol. Hematol. 55(7), 177-191 (2005).
7. Potti A, George DJ. Tyrosine kinase inhibitors in renal cell carcinoma. Clin. Cancer Res. 10 (Suppl. 18 Pt 2), 6371S-6376S (2004).
8. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 33(4), 322-406 (2006).
9. Sridhar SS, Hedley D, Siu. LL. Raf kinase as a target for anticancer therapeutics. Mol. Cancer Ther. 4(4), 677-685 (2005).
10. Deeks ED, Keating GM. Sunitinib. Drugs 66(17), 2255-2266 (2606).
11. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 25(7), 64-896 (2007).
12. Roskoski R Jr. Sunitinib: aVEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res Commun. 356(2), 323-328 (2007).
13. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111(9), 1287-1295 (2003).
14. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5(1), e19 (2008).
15. Abrams TJ, Lee LB, Murray LJ,Pryer-NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2 (5), 471-478 (2003).
16. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothclial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7(3), 225-233 (2004).
17. Potapova O, Laird AD, Nannini MA et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol. Cancer Ther. 5(5), 1280-1289 (2006).
18. Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18 (2), 338-340 (2004).
19. Grimaldi AM, Guida T, D'Attino R et al. Sunitinib: bridging present and future cancer treatment. Ann. Oncol. 18(Suppl. 6), vi31-vi34 (2007).
20. O'Brien MF, Russo P, Motzer R.J. Sunitinib therapy in renal cell carcinoma. BJU Int. 101 (11), 1339-1342 (2008).
21. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (1), 327-337 (2003).
22. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24(1), 25-35 (2006).
23. Houk BE, Bello CL, Michaelson MD et al. Exposure-response of sunitinib in metastatic renal cell carcinork (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. J. Clin. Oncol. 25(Suppl. 18), 5027 (2007).
24. Sutent® Prescribing information. 2008. Pfizer Labs. Division of Pfizer Inc. New York, NY, USA.
25. Meyer AJ, Hernandez A, Florl AR et al. Novel mutations of the von hippel-lindau tumor-suppressor gene rare-DNA hypermethylation in renal-cell carcinoma. cell lines of the clear-cell type. Int. J. Cancer 87, 650-653 (2000).
26. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib vs. interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
27. Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib vs. interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 26(Suppl.), 5024 (2008).
28. Bukowski RM, Eisen T, Szczylik C et al. Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J. Clin. Oncol. 25(Suppl.), 5023 (2007).
29. Kollmannsberger CK, Heng DY, Murray N, Chi KN. A population-based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone. J. Clin. Oncol. 25(Suppl. 18), 15572 (2007).
30. Heng DY, Chi KN, Murray N et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer (mRCC). Presented at: 2008 Genitourinary Cancers Symposium. San Francisco, CA, USA, 14-16 February 2008.
31. Remak E, Mullins CD, Akobundu E, Charbonneau C, Woodruff K. Economic evaluations of sunitinib vs. interferon-α (IFN-α) in first-line metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 25(Suppl. 18), 6607 (2007).
32. Remak E, Charbonneau C, Negrier S, Kim ST, Motzer Rj. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J. Clin. Oncol. 26, 3995-4000 (2008).
33. Benedict A, Charbonneau C, Hidi J, Kim ST, Negrier S. Economic evaluation of sunitinib, sorafenib, bevacizumab/interferon-α or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): an indirect comparison. J. Clin. Oncol. 26 (Suppl.), 5048 (2008).
34. Porta C, Szczylik D, Bracarda R et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic relan cell carcinoma (mRCC). J. Clin. Oncol. 26 (Suppl.), 5114 (2008).
35. Cchu TF, Rupnick MA, Kerkela R et al. Cardiotoxity associated with tyrosine kinase inhibitor sunitinib. Lancet 370(9604), 2011-2019 (2007).
36. Khakoo AY, Kassiotis CM, Tannir N et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112(11), 2500-2508 (2008).
37. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib.malate. Ann. Oncol. 19(9), 1613-1618 (2008).
38. Whitteles RM, Telli ML, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. J. Clin. Oncol. 26(Suppl.), 9597 (2008).
39. Gore ME, Porta C, Oudard S et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J. Clin. Oncol. 25(Suppl. 18), 5010 (2007).
40. Dallabrida SM, Ismail N, Pravda EA et al. Sunitinib-induced cardiotoxicity is mediated in part via direct effects on cardiac myocytes and smooth muscle cells.
41. Circulation 116(4), 11-311 (2007).
42. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann. Intern. Med. 145(9), 660-664 (2006).
43. Wolter F, Stefan C, Decallonne B et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br. J. Cancer 99, 448-454 (2008).
44. Shaheen PE, Tamaskar IR, Salas RN et al. Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J. Clin. Oncol. 24(Suppl.), 4605 (2006).
45. Schoeffski P, Wolter P, Himpe U et al. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. J. Clin. Oncol. 24(Suppl.), 3092 (2006).
46. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 99(1), 81-83 (2007).
47. Mannavola D, Coco P, Vannucchi G et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J. Clin. Endocrinol. Metab. 92(9), 3531-3534 (2007).
48. Wong E, Rosen LS, Mulay M et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17(4), 351-355 (2007).
49. Wolter P, Stefan C, Decallonne B et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). J. Clin. Oncol. 26(Suppl.), 5126 (2008).
50. Feldman DR, Martorella AJ, Robbins RJ, Motzer RJ. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 99(12), 974-975 (2007).
51. Hudes G, Carducci M, Tomczak P et al. A Phase 3, randomized, 3-arm study of tamsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR + IFM in the treatment of first-line, poor-risk patienti with advanced renal cell carcinoma (adv RCC). J. Clin. Oncol. 24, LBA4 (2006).
52. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370, 2103-2111 (2007).
53. Haas NB, Uzzo RG. The ASSURE trial - adjuvant sunitinib vs. sorafenib vs. placebo in patients with resected renal cell carcinoma. US Renal Genito-Urinary Dis. 54-56 (2006).
54. Michaelson M, Schwarzberg A, Ryan D et al. A Phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors. Presented at: 2008 Genitourinary Cancers Symposium. San Francisco, CA, USA, 14-16 February 2008.
55. Pandya SS, Mier JW, Cho D, McDermott D. The role of adding gemcitabine at time of sunitinib resistance in patients with metastatic renal cell cancer. Presented at: 2008 Genitourinary Cancers Symposium. San Francisco, CA, USA, 14-16 February 2008.
56. Allerton JP, Ebrahimi B, Schreeder MT et al. Phase I report from a multicenter trial of pgrifosine (PER1) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC). J. Clin. Oncol. 26(Suppl.), 14565 (2008).
57. Redman BG, Hudes GR, Kim ST, Chen I, Motzer RJ. Sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): updated results from a Phase I/II study. J. Clin. Oncol. 26(Suppl.), 16014 (2008).
58. Ryan CW, Curti BD, Pattee KJ, Besaw L, Beer TM, Fisher B. A dose-escalation Phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). Presented at: 2008 Genitourinary Cancers Symposium. San, Francisco, CA, USA, 14-16 February 2008.
59. Vance V, Amato RJ, Jac J, Saxena S, Willis JP, Chiang SB. A Phase I study of PEG-intron, sunitinib and tarceva in patients with metastatic renal cell cancer (MRCC). J. Clin. Oncol. 26(Suppl.), 14659 (2008).
60. Fischer P, Patel P, Carducci MA et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J. Clin. Oncol. 26(Suppl.), 16020 (2008).
61. Feldman DR, Ginsberg MS, Baum M et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26(Suppl.), 5100 (2008).
62. Schrader AJ, Olbert PJ, Hegele A, Varga Z, Hofmann R. Metastatic non-clear cell renal cell carcinoma: current therapeutic options. BJU Int. 101(11), 1343-1345 (2008).
63. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 26(1), 127-131 (2008).
64. Plimack ER, Jonasch E, Bekele BN, Smith LA, Araujo JC, Tannir NM. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): a Phase II study. J. Clin. Oncol. 26(Suppl.), 5112 (2008).